Under one in 10 individuals that would benefit from obesity jabs including Wegovy have access to them, warns the World Health Organization as it publishes its inaugural recommendations on the therapies.
With in excess of 1,000,000,000 people worldwide now obese, it is calling for increased and just availability to GLP-1 medication.
According to forecasts, in excess of 2,000,000,000 could be obese by 2030 if no action is taken.
"The latest guidelines recognises that obesity is a chronic disease that can be treated with thorough and lifelong support," stated WHO director-general Tedros Adhanom Ghebreyesus.
High costs, limited production capacity, and logistical bottlenecks are major hurdles to widespread availability to the treatments that can aid individuals in losing substantial body mass, explains the body.
GLP-1 Therapy Supply Crisis
Even under the current most favorable scenario, the production of such drugs might only reach about 100 million people – fewer than 10% of the global need, per the WHO.
The advice calls on countries and companies to expand availability, by approaches such as licensing agreements.
The intellectual property rights on a key compound – the core ingredient of the drug Wegovy – is due to expire in several nations in 2026.
The Way Obesity Drugs Work
These medications imitate a biological compound to delay gastric emptying, curb appetite and boost the sense of being full so individuals eat less.
Patients typically begin shedding pounds in the initial weeks of starting on the once-weekly jabs.
Studies suggests users may regain a significant portion a year later of halting the medication, when their typical hunger resume.
Being above a healthy weight elevates your likelihood for developing medical conditions, such as type 2 diabetes, heart disease, stroke, and specific malignancies.
Excess weight affects people in every country and was responsible for over three and a half million fatalities worldwide in 2024, according to the WHO.
